[{"address1": "280 East Grand Avenue", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "(650) 231-6625", "website": "https://www.alumis.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 128, "companyOfficers": [{"maxAge": 1, "name": "Mr. Martin  Babler Ph.D.", "age": 58, "title": "President, CEO & Chairman", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 701760, "exercisedValue": 0, "unexercisedValue": 12229563}, {"maxAge": 1, "name": "Dr. David M. Goldstein Ph.D.", "age": 57, "title": "Chief Scientific Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 499700, "exercisedValue": 0, "unexercisedValue": 1831528}, {"maxAge": 1, "name": "Mr. Roy C. Hardiman J.D.", "age": 63, "title": "Chief Business & Legal Officer", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 499700, "exercisedValue": 0, "unexercisedValue": 1694511}, {"maxAge": 1, "name": "Mr. John R. Schroer C.F.A.", "age": 58, "title": "Chief Financial Officer", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Derrick  Richardson", "age": 53, "title": "Senior VP and Head of People & Culture", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kenneth A. Brameld Ph.D.", "age": 50, "title": "Head of Discovery & Esker Fellow", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Claire  Langrish Ph.D.", "title": "Senior VP & Head of Immunology and Translational Science", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Philip  Nunn Ph.D.", "title": "Senior VP of Pharmacology & Project Team Leader", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jorn  Drappa M.D., Ph.D.", "age": 58, "title": "Chief Medical Officer & Head of Research and Development", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Roman G. Rubio M.D.", "age": 52, "title": "Senior VP & Head of Clinical Development & Translational Medicine", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 11.2, "open": 11.1, "dayLow": 10.7745, "dayHigh": 11.4, "regularMarketPreviousClose": 11.2, "regularMarketOpen": 11.1, "regularMarketDayLow": 10.7745, "regularMarketDayHigh": 11.4, "forwardPE": -1.6801802, "volume": 128400, "regularMarketVolume": 128400, "averageVolume": 169957, "averageVolume10days": 78140, "averageDailyVolume10Day": 78140, "bid": 10.85, "ask": 11.0, "bidSize": 200, "askSize": 100, "marketCap": 607142528, "fiftyTwoWeekLow": 9.54, "fiftyTwoWeekHigh": 13.53, "fiftyDayAverage": 11.6712, "twoHundredDayAverage": 11.890198, "currency": "USD", "enterpriseValue": 1073316160, "floatShares": 14737855, "sharesOutstanding": 47218400, "sharesShort": 2141166, "sharesShortPriorMonth": 1281783, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.0394, "heldPercentInsiders": 0.01205, "heldPercentInstitutions": 0.68401, "shortRatio": 7.85, "shortPercentOfFloat": 0.0574, "impliedSharesOutstanding": 54403300, "bookValue": -8.065, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -189034000, "trailingEps": -3.48, "forwardEps": -6.66, "enterpriseToEbitda": -5.8, "52WeekChange": -0.15789473, "SandP52WeekChange": 0.3593408, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ALMS", "underlyingSymbol": "ALMS", "shortName": "Alumis Inc.", "longName": "Alumis Inc.", "firstTradeDateEpochUtc": 1719581400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "7bc517b3-133f-3f7c-b6dd-349f2d478c1b", "messageBoardId": "finmb_705657695", "gmtOffSetMilliseconds": -14400000, "currentPrice": 11.19, "targetHighPrice": 36.0, "targetLowPrice": 29.0, "targetMeanPrice": 32.33, "targetMedianPrice": 32.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 209531008, "totalCashPerShare": 3.851, "ebitda": -185062000, "totalDebt": 31573000, "quickRatio": 6.298, "currentRatio": 6.73, "debtToEquity": 15.749, "operatingCashflow": -163520992, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-17"}]